Scilex Holding Company – NASDAQ:SCLX
Scilex Holding Company stock price today
$18.1
+17.71
+4541.03%
Financial Health
0
1
2
3
4
5
6
7
8
9
Market closed
Open in about 7 hours
Scilex Holding Company stock price monthly change
-79.90%
month
Scilex Holding Company stock price quarterly change
-79.90%
quarter
Scilex Holding Company stock price yearly change
-76.92%
year
Scilex Holding Company key metrics
Market Cap | 115.48M |
Enterprise value | N/A |
P/E | -68.42 |
EV/Sales | N/A |
EV/EBITDA | N/A |
Price/Sales | 48.22 |
Price/Book | 202.46 |
PEG ratio | -0.92 |
EPS | -0.88 |
Revenue | 47.04M |
EBITDA | -102.63M |
Income | -107.95M |
Revenue Q/Q | 2.85% |
Revenue Y/Y | 12.53% |
Profit margin | -61.43% |
Oper. margin | -133.13% |
Gross margin | 71.61% |
EBIT margin | -133.13% |
EBITDA margin | -218.17% |
Sign up &
create your own Smart Feed
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeScilex Holding Company stock price history
Scilex Holding Company stock forecast
Scilex Holding Company financial statements
| Jun 2023 | 12.58M | -26.64M | -211.8% |
|---|---|---|---|
| Sep 2023 | 10.11M | -35.52M | -351.18% |
| Dec 2023 | 13.46M | -21.4M | -158.97% |
| Mar 2024 | 10.88M | -24.37M | -223.97% |
| Mar 2024 | 10.88M | -24.37M | -223.97% |
|---|---|---|---|
| Sep 2025 | 30M | -7.00M | -23.34% |
| Oct 2025 | 23.85M | -12.80M | -53.67% |
| Dec 2025 | 26.15M | -10.24M | -39.16% |
Analysts Price target
Financials & Ratios estimates
| 2024-03-11 | -0.21 | -0.25 |
|---|---|---|
| 2024-05-13 | -0.12 | -0.26 |
| 2024-08-13 | -0.2 | -0.18 |
| 2024-12-10 | -0.2 | -0.1 |
| Jun 2023 | 126464000 | 116.04M | 91.76% |
|---|---|---|---|
| Sep 2023 | 80528000 | 243.19M | 302% |
| Dec 2023 | 101309000 | 274.24M | 270.7% |
| Mar 2024 | 91240000 | 281.02M | 308.01% |
| Jun 2023 | -13.47M | -7.97K | 43.53M |
|---|---|---|---|
| Sep 2023 | 5.9M | -155K | -38.89M |
| Dec 2023 | -5.36M | -166.17K | 8.26M |
| Mar 2024 | 9.39M | -150K | -11.19M |
Scilex Holding Company alternative data
| Aug 2023 | 100 |
|---|---|
| Sep 2023 | 100 |
| Oct 2023 | 100 |
| Nov 2023 | 100 |
| Dec 2023 | 109 |
| Jan 2024 | 109 |
| Feb 2024 | 109 |
| Mar 2024 | 105 |
| Apr 2024 | 105 |
| May 2024 | 105 |
| Jun 2024 | 106 |
| Jul 2024 | 106 |
Scilex Holding Company other data
100.00%
+99.60%
of SCLX is owned by hedge funds
51
+44
3.53M
+3.48M
shares is hold by hedge funds
What is insider trading?
| Period | Buy | Sel |
|---|---|---|
| May 2024 | 178579 | 0 |
| Oct 2024 | 115588 | 0 |
| Dec 2024 | 30000 | 0 |
| Transaction | Date | Insider | Security | Shares | Price per share | Total value | Source |
|---|---|---|---|---|---|---|---|
Purchase | SHAH JAISIM director, officer: See Remarks | Common Stock | 30,000 | $0.46 | $13,800 | ||
Purchase | JI HENRY director, officer.. | Common Stock | 8,888 | $0.94 | $8,355 | ||
Purchase | SHAH JAISIM director, officer: See Remarks | Common Stock | 32,000 | $0.99 | $31,680 | ||
Purchase | FOLLOWWILL DORMAN director | Common Stock | 1,000 | $0.99 | $990 | ||
Purchase | CHUN JAY director | Common Stock | 5,000 | $0.95 | $4,750 | ||
Purchase | WU YUE ALEXANDER director | Common Stock | 20,000 | $0.95 | $19,000 | ||
Purchase | LEMUS DAVID director | Common Stock | 2,000 | $0.9 | $1,800 | ||
Purchase | JI HENRY director, officer.. | Common Stock | 10,000 | $0.97 | $9,710 | ||
Purchase | SHAH JAISIM director, officer: See Remarks | Common Stock | 30,000 | $0.99 | $29,760 | ||
Purchase | MA STEPHEN HOI officer: Chief Financial Officer | Common Stock | 6,700 | $0.97 | $6,499 |
-
What's the price of Scilex Holding Company stock today?
One share of Scilex Holding Company stock can currently be purchased for approximately $18.1.
-
When is Scilex Holding Company's next earnings date?
Unfortunately, Scilex Holding Company's (SCLX) next earnings date is currently unknown.
-
Does Scilex Holding Company pay dividends?
No, Scilex Holding Company does not pay dividends.
-
How much money does Scilex Holding Company make?
Scilex Holding Company has a market capitalization of 115.48M and it's past years’ income statements indicate that its last revenue has increased compared to the previous period by 22.9% to 46.74M US dollars. Scilex Holding Company made a loss 114.33M US dollars in net income (profit) last year or -$0.1 on an earnings per share basis.
-
What is Scilex Holding Company's stock symbol?
Scilex Holding Company is traded on the NASDAQ under the ticker symbol "SCLX".
-
What is Scilex Holding Company's primary industry?
Company operates in the Healthcare sector and Drug Manufacturers - General industry.
-
How do i buy shares of Scilex Holding Company?
Shares of Scilex Holding Company can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
How many employees does Scilex Holding Company have?
As Jul 2024, Scilex Holding Company employs 106 workers, which is 1% more then previous quarter.
-
When Scilex Holding Company went public?
Scilex Holding Company is publicly traded company for more then 4 years since IPO on 5 Mar 2021.
-
What is Scilex Holding Company's official website?
The official website for Scilex Holding Company is scilexholding.com.
-
Where are Scilex Holding Company's headquarters?
Scilex Holding Company is headquartered at 960 San Antonio Road, Palo Alto, CA.
-
How can i contact Scilex Holding Company?
Scilex Holding Company's mailing address is 960 San Antonio Road, Palo Alto, CA and company can be reached via phone at +65 05164310.
Scilex Holding Company company profile:
Scilex Holding Company
scilexholding.comExchange:
NASDAQ
Full time employees:
113
Industry:
Drug Manufacturers - General
Sector:
Healthcare
Scilex Holding Company, a biopharmaceutical company, focuses on developing and commercializing non-opioid management products for the treatment of acute and chronic pain. Its commercial product is ZTlido 1.8%, a prescription lidocaine topical product for the relief of neuropathic pain related with post-herpetic neuralgia, which is a form of post-shingles nerve pain. It also offers SP-102, a viscous gel formulation of corticosteroid for epidural injections that is in a Phase III clinical trial to treat lumbosacral radicular pain; SP-103, which is in Phase II clinical trail for the treatment of low back pain; and SP-104, a novel low-dose delayed-release naltrexone hydrochloride formulation that has completed Phase I clinical trial for the treatment of fibromyalgia. The company is headquartered in Palo Alto, California. Scilex Holding Company is a subsidiary of Sorrento Therapeutics, Inc.
960 San Antonio Road
Palo Alto, CA 94303
Palo Alto, CA 94303
CIK: 0001820190
ISIN: US80880W1062
CUSIP: 80880W106
